Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

BACKGROUND: Nephrotic-range proteinuria (NRP) is associated with rapid kidney function loss and increased cardiovascular (CV) disease risk. We assessed the effects of linagliptin (LINA) on CV and kidney outcomes in people with Type 2 diabetes (T2D) with or without NRP. METHODS: Cardiovascular and re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanner, Christoph, Cooper, Mark E, Johansen, Odd Erik, Toto, Robert, Rosenstock, Julio, McGuire, Darren K, Kahn, Steven E, Pfarr, Egon, Schnaidt, Sven, von Eynatten, Maximilian, George, Jyothis T, Gollop, Nicholas D, Marx, Nikolaus, Alexander, John H, Zinman, Bernard, Perkovic, Vlado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857804/
https://www.ncbi.nlm.nih.gov/pubmed/33564423
http://dx.doi.org/10.1093/ckj/sfaa225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857804/
https://www.ncbi.nlm.nih.gov/pubmed/33564423
http://dx.doi.org/10.1093/ckj/sfaa225

Ejemplares similares